In Reply

Oncologist. 2020 May;25(5):e876. doi: 10.1634/theoncologist.2020-0059. Epub 2020 Mar 23.

Abstract

Bilen et al. respond to the letter by Köstek and Demir, agreeing that a deeper understanding of new biomarkers to evaluate immunotherapy outcome is necessary.

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Immunologic Factors
  • Immunotherapy
  • Inflammation
  • Neoplasms*
  • Sarcopenia*

Substances

  • Immunologic Factors